Monthly Archives: October 2014

OncoTherapy Network Highlights National Breast Cancer Awareness Month

Breast Cancer RibbonEvery October, National Breast Cancer Awareness Month [3] is observed to help spread the word about early detection. While screening is an integral part of breast cancer prevention, treatment options for thousands of patients diagnosed each year with breast cancer continues to be a focal point in oncology.

UBM Medica US announced that OncoTherapyNetwork [1], a leading online community to help oncologists and other clinicians gain a better understanding of the newest information available regarding the use of targeted therapies and immunotherapies, discusses some of the latest research on breast cancer treatment [2].

The featured articles below discuss some of the most recent research findings, including potential treatment options for both HER2-positive and triple-negative breast cancers:

• Neoadjuvant Carboplatin Boosts Targeted Therapy Responses in Triple-Negative Breast Cancer
The addition of neoadjuvant carboplatin to a regimen of taxane-anthracycline chemotherapy and targeted therapy substantially increased pathological complete responses in patients with stage II/III triple-negative breast cancer [4] (but not in patients with HER2-positive disease).

• Breast Cancer Vaccine Showing Promise in Women With HER2 Overexpression
Recent findings from a phase II randomized clinical trial demonstrates that a breast cancer vaccine known as GP2, may help at preventing disease recurrence in women with HER2 protein overexpression [5].

• Knockdown of CD24 May Enhance Efficacy of Targeted Agents in HER2-Positive Breast Cancer
Therapeutic targeting of CD24 may enhance the efficacy of targeted agents, such as trastuzumab and lapatinib, in treatment of human epidermal growth factor receptor 2 (HER2)-positive breast Cancer [6].

References:
1. www.oncotherapynetwork.com/?cid=pr10152014
2. www.oncotherapynetwork.com/breast-cancer-targets?cid=pr10152014

3. healthfinder.gov/nho/octobertoolkit.aspx
4. www.oncotherapynetwork.com/breast-cancer-targets/neoadjuvant-carboplatin-booststargeted-
therapy-responses-triple-negative-breast-cancer?cid=pr10152014
5. www.oncotherapynetwork.com/breast-cancer-targets/breast-cancer-vaccine-showingpromise-
women-her2-overexpression?cid=pr10152014
6. www.oncotherapynetwork.com/breast-cancer-targets/knockdown-cd24-may-enhanceefficacy-
targeted-agents-her2-positive-breast-cancer?cid=pr10152014
About UBM Medica US
Addressing today’s healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach — online, in print, via custom programs and live events. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers and payers resulting in improved quality of care for patients around the world. Through journals, magazines, online communities, live and digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Online communities include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, RheumatologyNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Americas which, through a range of aligned interactive environments, both physical and digital – increases business effectiveness for both customers and audiences through meaningful experiences, knowledge and connections. For more information, visit www.UBMMedicaUS.com.

RePubHub Banner

 

 

Got Questions? We have Answers! Contact us at CriteriumBlog@criteriuminc.com
(Reprinted with license and permission from PR Newswire.)

New Oncology Consortia Expand Translational Science Research Offerings

Criterium Inc Global CRO proudly announces our two newest Oncology Consortia Groups: ATOMIC (The Academic Thoracic Oncology Medical Investigator’s Consortium) focusing on Thoracic and Lung Cancers, and ABRCC (The Academic Breast Cancer Consortium), dedicated to Breast Cancer research. These new consortia consist of a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise. These two new consortia will join Criterium’s already successful AGICC (the Academic GI Cancer Consortium) directed by Dr. Wells Messersmith, established in 2008, and AMyC (the Academic Myeloma Consortium) established in 2010 with Dr. Brian G. M. Durie directing 3 high profile studies.

ALL Consortia Logos

All of Criterium’s Oncology Consortia specialize in translational research design to bring novel cancer therapies to market in accelerated time frames. “These new types of therapies allow cancer drugs to more effectively target only the destructive cancer cells, while allowing healthy cells to remain untouched, thereby providing a less toxic treatment, with better patient survival outcomes,” stated Dr. Jack Macdonald, the Senior Medical Consultant for the Oncology Consortia.

Dr. D. Ross Camidge MD PHD ATOMIC

Dr. D. Ross Camidge of the University of Colorado’s Cancer Center in Aurora, Colorado has been appointed as ATOMIC’s Director. “ATOMIC brings together a powerful mixture of mature thought leaders and the next generation of experts with the sole goal of designing and completing clinical trials that will change the way we do business in thoracic oncology for the better,” says Camidge.

Also from the University of Colorado is Dr. Peter Kabos, Dr Peter Kabos MD ABRCCthe newly named Director for ABRCC. “ABRCC is an academic consortium formed for the new era of clinical trial design and implementation. Our goal is to rapidly translate advances in breast cancer research into targeted therapies that will benefit our patients,” states Kabos. Both bring an exceptional set of credentials in advanced research and organizational skills to the collaboration.

The Consortia Model for research and development in pharmaceuticals utilizes translational science methodologies to streamline cancer research.  The Consortia rosters are presently represented by Key Opinion Leaders (KOLs) and Top Investigators at 24 of the most prestigious institutions in the USA. In this way, Criterium brings together these physician-scientists into highly effective and productive new drug development entities. To learn more, please visit: www.CriteriumInc.com/OCC.php

Got Questions? We have Answers! Contact us at CriteriumBlog@criteriuminc.com